These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38482511)

  • 1. Recognition, Description, and Variability of Spasticity in Individuals With Multiple Sclerosis and Potential Barriers to Clinician-Patient Dialogue: Results From SEEN-MSS, a Large-Scale, Self-Reported Survey.
    Thrower B; Newsome SD; Hendin B; Danese S; Patterson J; Chinnapongse R
    Int J MS Care; 2024; 26(2):75-80. PubMed ID: 38482511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptom burden, management and treatment goals of people with MS spasticity: Results from SEEN-MSS, a large-scale, self-reported survey.
    Newsome SD; Thrower B; Hendin B; Danese S; Patterson J; Chinnapongse R
    Mult Scler Relat Disord; 2022 Dec; 68():104376. PubMed ID: 36544321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an integrated conceptual model of multiple sclerosis spasticity.
    Cameron MH; Bethoux F; Field-Fote E; Lenderking WR; Zaiser E; Cutts KN; Wagner JM; Berwaerts J; Steinerman JR
    Disabil Rehabil; 2024 Jun; 46(13):2955-2965. PubMed ID: 37480330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spasticity in multiple sclerosis: results of a patient survey.
    Oreja-Guevara C; González-Segura D; Vila C
    Int J Neurosci; 2013 Jun; 123(6):400-8. PubMed ID: 23297730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spasticity in patients with multiple sclerosis--clinical characteristics, treatment and quality of life.
    Flachenecker P; Henze T; Zettl UK
    Acta Neurol Scand; 2014 Mar; 129(3):154-62. PubMed ID: 24256407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Multiple Sclerosis Spasticity Scale 88: A Short Report.
    Freeman J; Gorst T; Ofori J; Marsden J
    Rehabil Process Outcome; 2019; 8():1179572718823510. PubMed ID: 34497457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity.
    Jacinto J; Varriale P; Pain E; Lysandropoulos A; Esquenazi A
    Front Neurol; 2020; 11():388. PubMed ID: 32477251
    [No Abstract]   [Full Text] [Related]  

  • 8. A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis.
    Bethoux F; Marrie RA
    Patient; 2016 Dec; 9(6):537-546. PubMed ID: 27154536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat
    Fernandez O; Costa-Frossard L; Martínez-Ginés ML; Montero P; Prieto-González JM; Ramió-Torrentà L
    Front Neurol; 2021; 12():722801. PubMed ID: 34646229
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-interventional, prospective, observational study on spasticity-associated symptom control with nabiximols as add-on therapy in patients with multiple sclerosis spasticity in Austria.
    Guger M; Hatschenberger R; Leutmezer F
    Brain Behav; 2023 Apr; 13(4):e2947. PubMed ID: 36934456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis spasticity: 'state-of-the-art' questionnaire survey of specialized healthcare professionals.
    Collongues N; Vermersch P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):21-5. PubMed ID: 23369056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients' experiences of self-identification, seeking support, and anticipation of potential relapse in multiple sclerosis.
    Wicks CR; Sloan R; DiMauro S; Thompson EL; Billington S; Webb M; Pepper G
    Mult Scler Relat Disord; 2021 Nov; 56():103259. PubMed ID: 34628265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis.
    Tintoré M
    Neurodegener Dis Manag; 2015; 5(6 Suppl):15-7. PubMed ID: 26611266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment and Measurement of Spasticity in MS: State of the Evidence.
    Hugos CL; Cameron MH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(10):79. PubMed ID: 31471769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of selected multiple sclerosis symptoms with disability and quality of life: a large Danish self-report survey.
    Gustavsen S; Olsson A; Søndergaard HB; Andresen SR; Sørensen PS; Sellebjerg F; Oturai A
    BMC Neurol; 2021 Aug; 21(1):317. PubMed ID: 34399707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the Experience of Spasticity after Spinal Cord Injury: A National Survey Project of the Spinal Cord Injury Model Systems Centers.
    Field-Fote EC; Furbish CL; Tripp NE; Zanca JM; Dyson-Hudson T; Kirshblum S; Heinemann AW; Chen D; Felix ER; Worobey L; Schmidt-Read M; Marino RJ; Hayat MJ
    Arch Phys Med Rehabil; 2022 Apr; 103(4):764-772.e2. PubMed ID: 34015348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).
    Hobart JC; Riazi A; Thompson AJ; Styles IM; Ingram W; Vickery PJ; Warner M; Fox PJ; Zajicek JP
    Brain; 2006 Jan; 129(Pt 1):224-34. PubMed ID: 16280352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of nabiximols oromucosal spray (Sativex
    Garde N; Heibel M
    Drugs Context; 2024; 13():. PubMed ID: 38384931
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.